168 related articles for article (PubMed ID: 30244077)
1. Results of the effectiveness of two piperacillin-tazobactam molecules in the real world.
Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME
Int J Infect Dis; 2018 Nov; 76():91-96. PubMed ID: 30244077
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of generic formulation of piperacillin/tazobactam (Astaz-P) for treatment of infected patients at Siriraj Hospital.
Charoenpong L; Tongsai S; Thamlikitkul V
J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S104-10. PubMed ID: 23590029
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
4. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
5. Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review.
Petersen MW; Perner A; Sjövall F; Jonsson AB; Steensen M; Andersen JS; Achiam MP; Frimodt-Møller N; Møller MH
Acta Anaesthesiol Scand; 2019 Aug; 63(7):973-978. PubMed ID: 31020663
[TBL] [Abstract][Full Text] [Related]
6. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Chen GJ; Pan SC; Foo J; Morel C; Chen WT; Wang JT
J Microbiol Immunol Infect; 2019 Oct; 52(5):807-815. PubMed ID: 31029529
[TBL] [Abstract][Full Text] [Related]
7. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
Schmees PM; Bergman SJ; Strader BD; Metzke ME; Pointer S; Valenti KM
Am J Health Syst Pharm; 2016 Jun; 73(11 Suppl 3):S100-5. PubMed ID: 27208142
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
[TBL] [Abstract][Full Text] [Related]
10. Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study.
Meier N; Munch MW; Granholm A; Perner A; Hertz FB; Venkatesh B; Hammond NE; Li Q; De Bus L; De Waele J; Kauzonas E; Sjövall F; Møller MH; Helleberg M
Acta Anaesthesiol Scand; 2024 Jul; 68(6):821-829. PubMed ID: 38549422
[TBL] [Abstract][Full Text] [Related]
11. Evaluating vancomycin and piperacillin-tazobactam in ED patients with severe sepsis and septic shock.
Le C; Chu F; Dunlay R; Villar J; Fedullo P; Wardi G
Am J Emerg Med; 2018 Aug; 36(8):1380-1385. PubMed ID: 29321120
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
13. Meropenem versus piperacillin-tazobactam for the treatment of pancreatic necrosis.
Racketa S; Gandhi K; Lambie M
Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116209. PubMed ID: 38458097
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia.
Wang CY; Chen CH; Tu CY; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Lai CC
J Infect Public Health; 2022 Sep; 15(9):961-965. PubMed ID: 35930932
[TBL] [Abstract][Full Text] [Related]
17. Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection.
Ferreiro JLL; Otero JÁ; Rivo AS; González LG; Conde IR; Soneira MF; García JP; de la Fuente Aguado J
Sci Rep; 2021 Apr; 11(1):8610. PubMed ID: 33883671
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A
BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524
[TBL] [Abstract][Full Text] [Related]
19. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
20. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis.
Fawaz S; Barton S; Nabhani-Gebara S
BMC Infect Dis; 2020 Jun; 20(1):430. PubMed ID: 32563242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
